Arnav Lakkimsetti
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Role not yet determined Is this you? Add your title
Research Areas
Biography and Research Information
OverviewAI-generated summary
Arnav Lakkimsetti's research focuses on the comparative analysis of targeted therapies in B-cell malignancies. Their work includes a study comparing the mortality and toxicity of ibrutinib, acalabrutinib, and zanubrutinib in real-world settings for patients with these blood cancers. This research aims to provide insights into the comparative effectiveness and safety profiles of these medications.
Metrics
- Publications: 2
Selected Publications
-
POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity (2026)
-
CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity (2026)
Collaboration Network
Top Collaborators
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
- POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity
Similar Researchers
Based on overlapping research topics